Research Services was Fate Therapeutics’s largest product and service line in fiscal 2019, bringing in $6.90M of $10.70M (64%).
| Product and Service | FY 2016 | FY 2017 | FY 2018 | FY 2019 |
|---|---|---|---|---|
| Research Services | $2.30M | $2.00M | $2.40M | $6.90M |
| Upfront Fee & Equity Premium | $2.10M | $2.10M | $2.10M | $700.00K |
| Upfront Fee | — | — | $200.00K | $3.10M |
| Total | $4.40M | $4.10M | $4.70M | $10.70M |
Fate Therapeutics brought in $10.70M from its three product and service lines in fiscal 2019, the year ended December 31, 2019. That was up 127.7% from $4.70M in fiscal 2018. Research Services was the largest at $6.90M (64.5%), ahead of Upfront Fee at $3.10M (29.0%) and Upfront Fee & Equity Premium at $700.00K (6.5%).
Compared with fiscal 2018, Upfront Fee grew fastest, up 1,450.0% to $3.10M, while Upfront Fee & Equity Premium fell the most, down 66.7% to $700.00K.
Fate Therapeutics began breaking out Upfront Fee in fiscal 2018, when it brought in $200.00K.
Fate Therapeutics (FATE) reports its revenue by product and service. In fiscal 2019, Research Services was its largest product and service line, bringing in $6.90M (64.5% of the total), followed by Upfront Fee at $3.10M (29.0%).
Research Services was Fate Therapeutics' largest product and service line in fiscal 2019, bringing in $6.90M, or 64.5% of the $10.70M total across its three product and service lines.
Among Fate Therapeutics' product and service lines that make up at least 2% of revenue, Upfront Fee grew fastest in fiscal 2019, up 1,450.0% from $200.00K to $3.10M.
Every figure comes from Fate Therapeutics' annual financial filings, as reported. Each line keeps the name Fate Therapeutics gives it, and years follow its fiscal calendar.
Fate Therapeutics' revenue by product and service goes back to fiscal 2016, with figures through fiscal 2019. The latest four fiscal years are free to view, and the full history is available with a Business Quant subscription.